Overview
What is Research Foundation For The Treatment Of Ovarian Cancer Inc?
Research Foundation for the Treatment of Ovarian Cancer Inc. is a nonprofit organization, headquartered at 47 Charlotte Road, Newton, Massachusetts 02459. Their primary focus is on ovarian cancer research and education, with the goal of promoting novel therapies. To achieve this objective, they have provided a donation to Dr. Kipp Weiskopf's lab at the Whitehead Institute. This funding supports the lab's efforts to eradicate ovarian cancer in mice using a combined administration of anti-CD47 and anti-CD24, without causing significant hematologic toxicity. Additionally, the foundation is aiding the development of humanized bispecific antibodies that bind CD47 and/or CD24 and an ovarian-cancer tumor antigen. By investing in cutting-edge research, the foundation aims to contribute to the advancement of ovarian cancer treatment.
Is Research Foundation For The Treatment Of Ovarian Cancer Inc legitimate?
Research Foundation For The Treatment Of Ovarian Cancer Inc is a legitimate nonprofit organization registered as a 501(c)(3) entity. Research Foundation For The Treatment Of Ovarian Cancer Inc submitted a form 990, which is a tax form used by tax-exempt organizations in the U.S., indicating its operational transparency and adherence to regulatory requirements. Donations to this organization are tax deductible.
Heare are some key statistics you may want to consider:
Executive Compensation: $0
Professional Fundraising Fees: $0
Other Salaries and Wages: $0
For more financial information, click here
What is the mission statement of Research Foundation For The Treatment Of Ovarian Cancer Inc?
The Research Foundation for the Treatment of Ovarian Cancer Inc's primary focus is on ovarian cancer research and education with the aim of promoting novel therapies. The foundation supports research initiatives, such as contributing to Dr. Kipp Weiskopf's lab at the Whitehead Institute. Specifically, their donation is intended to assist in eradicating ovarian cancer in mice through the combined administration of anti-CD47 and anti-CD24 without causing significant hematologic toxicity. Furthermore, they aim to develop humanized bispecific antibodies that bind to CD47, CD24, and ovarian cancer tumor antigens. This work aims to advance the development of more effective treatments for ovarian cancer.
Who is the CEO of Research Foundation For The Treatment Of Ovarian Cancer Inc?
Richard Kronish is the President of Research Foundation For The Treatment Of Ovarian Cancer Inc.
What is the revenue of Research Foundation For The Treatment Of Ovarian Cancer Inc?
Research Foundation For The Treatment Of Ovarian Cancer Inc's revenue in 2022 was $262,176.
Who are the executives of Research Foundation For The Treatment Of Ovarian Cancer Inc and what are their salaries?
Here are 4 key members and their salaries:
- Compensation: $0
- Related: $0
- Other: $0
- Compensation: $0
- Related: $0
- Other: $0
- Compensation: $0
- Related: $0
- Other: $0
- Compensation: $0
- Related: $0
- Other: $0
Where can I find the form 990 for Research Foundation For The Treatment Of Ovarian Cancer Inc?
Research Foundation For The Treatment Of Ovarian Cancer Inc's most recent form 990 was submitted in 2022 and can be accessed here.
Mission Statement of Research Foundation For The Treatment Of Ovarian Cancer Inc
The Research Foundation for the Treatment of Ovarian Cancer Inc is dedicated to advancing ovarian cancer research and education with the ultimate goal of promoting novel therapies. This nonprofit organization's mission is to support innovative research conducted by Dr. Kipp Weiskopf's lab at the Whitehead Institute. The foundation's contribution aims to assist the lab in eradicating ovarian cancer in mice through the combined administration of anti-CD47 and anti-CD24 without causing substantial hematologic toxicity. Additionally, the foundation is supporting the development of humanized bispecific antibodies that bind CD47 and/or CD24 and an ovarian-cancer tumor antigen. This research holds the potential to revolutionize the treatment of ovarian cancer, offering hope for those affected by this devastating disease.
Shop smarter and support your favorite cause with the Give Freely browser extension. Save money with coupons and donate to charity with a single click. Download now!
Impact
October, 2024
The Research Foundation For The Treatment Of Ovarian Cancer Inc significantly impacts the field of ovarian cancer research through its focused efforts on innovative treatment approaches. By financing cutting-edge research, such as the donation to Dr. Kipp Weiskopf's lab at the Whitehead Institute, the foundation is instrumental in advancing the development of novel therapies aimed at eradicating ovarian cancer.
The specific initiatives supported by the foundation aim to explore the potential of combined therapies using anti-CD47 and anti-CD24 antibodies. This research holds the promise of treating ovarian cancer in mouse models without inducing severe hematologic toxicity, which could pave the way for safer treatments in humans. Additionally, the development of humanized bispecific antibodies targeting both CD47 or CD24 and ovarian cancer tumor antigens represents a promising avenue for creating more effective and targeted therapies.
Through these efforts, the foundation not only fosters significant advancements in medical research but also raises awareness about ovarian cancer and promotes education surrounding its treatment, thereby contributing to the overall improvement in patient outcomes.
This information is meant to be a general summary of Research Foundation For The Treatment Of Ovarian Cancer Inc. Please take the time to review official sources before making any decisions based upon the content provided here.
Financials
This financial information is from Propublica.
Other financial information:
This information is from the most recently submitted tax form from this organization, which was in 2022.
- Investment Income: $14,904
- Gross Receipts: $358,650
Assets and Liabilities:
- Total Assets: $2,184,004
- Total Liabilities: $0
- Net Assets: $2,184,004
Want to help this charity, for free? You can click here to learn more about Give Freely
Organization Details
Founding Year
2000
Phone
(617) 699-7914Principal Officer
Richard Kronish
Main Address
47 CHARLOTTE ROAD, NEWTON, MA, 02459
NTEE Category
Code: H123 - Medical research
If you are a representative of Research Foundation For The Treatment Of Ovarian Cancer Inc and wish to learn more about how Give Freely can help you raise funds, please click here: https://givefreely.com/nonprofits/. Our services are offered at no cost to your organization.